Managing Patients Diagnosed with Thrombophilia Following an Acute Thrombotic Episode

Abstract

Trombofilia Thrombophilia is a pathological condition characterized by excessive tendency to hypercoagulability occurring as a result of a hereditary and/ or acquired predisposition and is based on changes in coagulation balance. Due to the lack of conclusive evidence supporting clinical testing benefits for inherited thrombophilia, future studies are likely to focus on new strategies to identify and classify patients with hypercoagulability states. Most recommendations for antithrombotic therapy in children are based on extrapolation of results from randomised studies in adults or from small cross-sectional clinical trials and mainly retrospectives in children. Although antithrombotic therapy in children usually follows the same indications as in adults, the distribution of diseases requiring antithrombotic therapy differs in children and adolescents.. Patients with thrombophilia and a history of thrombotic event (such as deep vein thrombosis, pulmonary thrombembolism, or stroke) may benefit from various lifestyle changes as well as drug treatment to reduce the risk of future thrombotic episodes and improve overall cardiovascular health. However, it is important to note that specific recommendations may vary depending on the individual's medical history, the severity of thrombophilia, and any other associated pathologies. The identification of risk factors associated with thrombophilia could lead to the indication of prophylaxis for asymptomatic patients with a family history of early thrombosis and high-risk thrombophilia. These strategies would have the advantage of being able to assess the interaction between inherited and acquired factors and could probably lead to individualised thrombotic risk profiling.